Back to Search
CHIHIRO MORISHIMA, MD
MD
Clinical & Laboratory Immunology (Internal Medicine) Physician
NPI: 1295077287IndividualAccepts Medicare
Specialties, Licenses & Credentials
Clinical & Laboratory Immunology (Internal Medicine) PhysicianPrimary
Internal Medicine — Clinical & Laboratory Immunology
Code: 207RI0001X
MD00028475(WA)
Education
OTHER
Class of 1988
Research & Publications (20)
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.
PMID 18816437·Hepatology·2008
8-other
Preservation of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses despite global loss of CD4+ T cells in HCV/HIV coinfection.
PMID 17624844·J Infect Dis·2007
4-observational
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
PMID 16871570·Hepatology·2006
2-rct
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
PMID 16518754·J Infect Dis·2006
2-rct
Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing.
PMID 16496327·Hepatology·2006
8-other
Strengths and limitations of commercial tests for hepatitis C virus RNA quantification.
PMID 14715796·J Clin Microbiol·2004
8-other
Hepatitis C virus-specific cytolytic T cell responses after antiviral therapy.
PMID 14499244·Clin Immunol·2003
4-observational
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
PMID 19676128·Hepatology·2009
8-other
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
PMID 19291787·Hepatology·2009
2-rct
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
PMID 18848939·Gastroenterology·2009
8-other
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
PMID 19052125·N Engl J Med·2008
4-observational
Antiviral effects of silymarin against hepatitis C: the jury is still out.
PMID 18509876·Hepatology·2008
8-other
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
PMID 18237873·Clin Gastroenterol Hepatol·2008
8-other
Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy.
PMID 17949270·AIDS Patient Care STDS·2007
5-case
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.
PMID 17484885·Gastroenterology·2007
8-other
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
PMID 17296533·Clin Gastroenterol Hepatol·2007
4-observational
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
PMID 17133499·Hepatology·2006
4-observational
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C.
PMID 17101320·Gastroenterology·2006
3-trial
High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection.
PMID 16453262·J Infect Dis·2006
8-other
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.
PMID 15986415·Hepatology·2005
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1959 NE PACIFIC ST
SEATTLE, WA 98195 - Phone
- (206) 543-6420
Quick Facts
- NPI
- 1295077287
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 38
- Publications
- 20
Are you this provider?
Claim Your Profile